Compare Enveric Biosciences Inc (ENVB) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Symbotic Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Symbotic Inc trades at $42.63 (market cap $5.46B). The key difference: Symbotic Inc is far larger — about 802.9× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 1,965,805). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Symbotic Inc for 23 Days on average.
| ENVB | SYM | |
|---|---|---|
Market Cap | $6.80M | $5.46B |
Volume | 64,867 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $10.80 | $87.30 |
52-Week Low | $1.27 | $38.22 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | -$1.49M | $3.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
SYM trades at $42.63, down 1.57% today, with bearish technical signals dominating (15 sell vs 2 buy indicators). The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M and thin 0.31% net margin. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains bullish with $60.33 price target despite technical weakness.
SYM presents a growth story with $22.5B backlog and expanding AI/robotics market positioning, but faces execution risks from customer concentration (85% Walmart revenue) and profitability challenges. The stock trades at premium valuations (P/E 1,051.5, EV/EBITDA 74.05) requiring significant future earnings growth to justify. Near-term support at $40-42 levels critical for maintaining current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
